Table 1 Baseline characteristics of patients with prostate cancer according to Vimentin CTC status
Characteristic | Vimentin CTC-negative patients (no vimentin + ve CTCs) (%) | Vimentin CTC-positive patients (≥1 vimentin + ve CTC) (%) |
|---|---|---|
Total patient numbers | 63 | 30 |
Age, years | ||
 Median | 76 | 72 |
 Range | 48–93 | 53–86 |
Number of metastasic sites | ||
 1 | 26/63 (41.3) | 11/30 (36.7) |
 2 | 21/63 (33.3) | 9/30 (30) |
 3+ | 15/63 (23.8) | 10/30 (33.3) |
 Not stated | 1/63 (1.6) | 0/30 (0) |
Metastasic sites | Â | Â |
 Lymph Nodes alone | 3/63 (4.8) | 1/30 (3.3) |
 Bone alone | 24/63 (38.1) | 10/30 (33.3) |
 Bone and lymph nodes | 17/63 (27) | 6/30 (20) |
 Visceral/multiple sites | 19/63 (30.2) | 13/30 (43.3) |
Treatment at time of 1st CTC specimen | ||
 Cabazitaxel | 7/63 (11.1) | 7/30 (23.3) |
 Docetaxel | 7/63 (11.1) | 3/30 (10) |
 Abiraterone | 26/63 (41.3) | 11/30 (36.7) |
 Enzalutamide | 5/63 (7.9) | 2/30 (6.7) |
 Radium 223 | 2/63 (3.2) | 2/30 (6.7) |
 Others/Not Stated | 16/63 (25.4) | 5/30 (16.7) |
Line of treatment at time of 1st CTC specimen | ||
 1 | 10/63 (15.9) | 4/30 (13.3) |
 2 | 17/63 (27) | 8/30 (26.7) |
 3+ | 14/63 (22.2) | 12/30 (40) |
 Not stated | 22/63 (34.9) | 6/30 (20) |
Previous treatments | ||
 Primary surgery | 10/63 (15.9) | 7/30 (23.3) |
 Primary radiotherapy | 27/63 (42.9) | 12/30 (40) |
 Docetaxel | 42/63 (66.7) | 23/30 (76.7) |
 Enzalutamide | 2/63 (3.2) | 4/30 (13.3) |
 Cabazitaxel | 10/63 (15.9) | 7/30 (23.3) |
 Abiraterone | 21/63 (33.3) | 12/30 (40) |
Total CTC levels at baseline | ||
 Mean | 98.8 | 492.6 |
 Range | 0–1185 | 1–4310 |